Business
INOVIO to Participate in Upcoming Scientific Conferences
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present data at a number of upcoming scientific conferences, highlighting key aspects of lead product candidate INO-3107 for RRP. INOVIO has begun the rolling submission of its Biologics License Application (BLA) for INO-3107, which it anticipates completing in the second hal
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent Respiratory Papillomatosis (RRP)","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional presentations focus on promise of next-generation DNA medicine technology, including the first preclinical data describing potential for DNA-encoded protein technology (DPROT) to address Hemophilia A","length":210,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false},{"type":"text","content":"PLYMOUTH MEETING, Pa., Sept. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present data at a number of upcoming scientific conferences, highlighting key aspects of lead product candidate INO-3107 for RRP. INOVIO has begun the rolling submission of its Biologics License Application (BLA) for INO-3107, which it anticipates completing in the second half of 2025 with the goal of file acceptance by the U.S. Food and Drug Administration by the end of 2025.","length":662,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yd1bAc6HmDvRUbv9UGxnLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d","width":400,"height":129}},"href":"https://mma.prnewswire.com/media/2310866/INOVIO_v1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"INOVIO also plans to highlight its next-generation DNA-medicine technology, including presentations on a Phase 1 clinical trial of a DNA-encoded monoclonal antibody (DMAb) product candidate and new preclinical data on DPROTs addressing Hemophilia A.","length":249,"tagName":"p"},{"type":"text","content":" Presentations on INO-3107 for RRP :","length":36,"tagName":"p"},{"type":"text","content":"Ame...